Keywords
anaplastic thyroid carcinoma, tumorigenesis, taxanes, microtubules, cell cycle, intracellular messengers, apoptosis.
How to Cite
Tronko, M., Pushkarev, V., Kovzun, O., & Pushkarev, V. (2013). Anaplastic carcinoma of the thyroid gland: new approaches for its treatment (review ). Endokrynologia, 18(2), 78-91. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/395
Abstract
The review presents analysis of last decade data on the mechanisms of anaplastic thyroid carcinoma tumorigenesis and cancerostatic action of taxanes on malignant cells. The role of different signaling cascades and cell cycle regulatory mechanisms in mediating of effects of taxanes in the tumor cell was shown. Data on paclitaxel action upon thyroid anaplastic cancer cells that reveal the mechanism of induction of apoptosis are presented. The involvement of different messenger cascades into pro- and antiapoptotic processes initiated by taxanes in the cell are discussed.
References
1. Tronko M., Bogdanova T., Voskoboynyk L. et al. Radiation induced thyroid cancer: fundamental and applied aspects // Exp. Oncol. 2010, 32, N3, 200-204.
2. Downing K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics // Ann. Rev. Cell Dev. Biol. 2000, 16, 89-111.
3. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs // Nat. Rev. Cancer. 2004, 4, 253-265.
4. Kingston D.G.I. The shape of things to come: Structural and synthetic studies of taxol and related compounds // Phytochemistry. 2007, 68, 1844-1854.
5. Rowinsky E.K. The development and clinical utility of the taxane class of an microtubule chemotherapy agents // Ann. Rev. Med. 1997, 48, 353-374.
6. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninetysix-hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group // Thyroid. 2000, 10, N 7, 587-594.
7. Pushkarev V.M., Starenki D.V., Saenko V.A. et al. Molecular mechanism of the effects of low concentrations of taxol in anaplastic thyroid cancer cells // Endocrinology. 2004, 145, N 7, 3143-3152.
8. Kebebew E., Greenspan F.S., Clark O.H. et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors // Cancer. 2005, 103, 1330-1335.
9. Hundahl S.A., Cady B., Cunningham M.P. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study // Cancer. 2000, 89, 202-217.
10. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States. 1973–2002 // J. Am.Med.Assoc. 2006, 295, 2164-2167.
11. Besic N., Hocevar M., Zgajnar J. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia // Thyroid. 2010, 20, 623-626.
12. Богданова Т.И., Козырицкий В.Г., Тронько Н.Д. Патология щитовидной железы у детей. К.: Чернобыльинтеринформ, 2000. 158 с.
13. Smallridge R.C. Approach to the patient with anaplastic thyroid carcinoma // J. Clin. Endocr. Metab. 2012, 97, N8, 2566-2572.
14. Ryder M., Ghossein R.A., Ricarte-Filho J.C. et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer // Endocr. Relat. Cancer. 2008, 15, N 4, 1069-1074.
15. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia // Nat. Rev. Cancer. 2006, 6, 292-306.
2. Downing K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics // Ann. Rev. Cell Dev. Biol. 2000, 16, 89-111.
3. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs // Nat. Rev. Cancer. 2004, 4, 253-265.
4. Kingston D.G.I. The shape of things to come: Structural and synthetic studies of taxol and related compounds // Phytochemistry. 2007, 68, 1844-1854.
5. Rowinsky E.K. The development and clinical utility of the taxane class of an microtubule chemotherapy agents // Ann. Rev. Med. 1997, 48, 353-374.
6. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninetysix-hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group // Thyroid. 2000, 10, N 7, 587-594.
7. Pushkarev V.M., Starenki D.V., Saenko V.A. et al. Molecular mechanism of the effects of low concentrations of taxol in anaplastic thyroid cancer cells // Endocrinology. 2004, 145, N 7, 3143-3152.
8. Kebebew E., Greenspan F.S., Clark O.H. et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors // Cancer. 2005, 103, 1330-1335.
9. Hundahl S.A., Cady B., Cunningham M.P. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study // Cancer. 2000, 89, 202-217.
10. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States. 1973–2002 // J. Am.Med.Assoc. 2006, 295, 2164-2167.
11. Besic N., Hocevar M., Zgajnar J. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia // Thyroid. 2010, 20, 623-626.
12. Богданова Т.И., Козырицкий В.Г., Тронько Н.Д. Патология щитовидной железы у детей. К.: Чернобыльинтеринформ, 2000. 158 с.
13. Smallridge R.C. Approach to the patient with anaplastic thyroid carcinoma // J. Clin. Endocr. Metab. 2012, 97, N8, 2566-2572.
14. Ryder M., Ghossein R.A., Ricarte-Filho J.C. et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer // Endocr. Relat. Cancer. 2008, 15, N 4, 1069-1074.
15. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia // Nat. Rev. Cancer. 2006, 6, 292-306.
Downloads
Download data is not yet available.